To study if a Mediterranean diet (MD) followed by lean donor fecal microbiota transplantation (FMT) has synergistic superior beneficial effects on peripheral insulin sensitivity and (small) intestinal microbiota composition as compared to…
ID
Bron
Verkorte titel
Aandoening
metabolic syndrome
insulin resistance
microbiota
mediterranean diet
Ondersteuning
Onderzoeksproduct en/of interventie
Uitkomstmaten
Primaire uitkomstmaten
Effect of mediterranean diet followed by lean donor FMT versus mediterranean diet followed by autologous FMT on intestinal microbiota composition at 0,3,6, and 12 weeks .
Achtergrond van het onderzoek
Previous research has shown that faecal microbiota transplantation of lean healthy donors improves insulin sensitivity (Vrieze et al., 2012) and recent data have suggested that engraftment of beneficial lean donor bacterial differs between metabolic syndrome subjects (Li-Nieuwdorp, Science 2016). Since diet is thought to be of pivotal importance in stabilizing gutmicrobiota composition (David et al., 2014; De Filippis et al., 2015) we hypothesize that prescription of a healthy (Mediterranean) diet before lean donor fecal transplantation will allow enhanced engraftment of beneficial bacteria in the intestine of metabolic syndrome subject and will have a synergistic beneficial effect on peripheral insulin sensitivity.
Doel van het onderzoek
To study if a Mediterranean diet (MD) followed by lean donor fecal microbiota transplantation (FMT) has synergistic superior beneficial effects on peripheral insulin sensitivity and (small) intestinal microbiota composition as compared to prescription of Mediterranean diet (MD) followed by autologous (own) FMT in male subjects with metabolic syndrome.
Onderzoeksopzet
0.6 weeks
Onderzoeksproduct en/of interventie
fecal transplantation (allogeneic/lean donor or autologous) on top of mediterranean diet
Publiek
MEIBERGDREEF 9, KAMER F4.159.2
M. Nieuwdorp
Amsterdam 1105 AZ
The Netherlands
+31 (0)20 5666612
m.nieuwdorp@amc.uva.nl
Wetenschappelijk
MEIBERGDREEF 9, KAMER F4.159.2
M. Nieuwdorp
Amsterdam 1105 AZ
The Netherlands
+31 (0)20 5666612
m.nieuwdorp@amc.uva.nl
Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)
-Male obese subjects with metabolic syndrome
-21 to 65 years-old
-body mass index (BMI) 30 to 43 kg/m2)
-3 out of 5 NCEP metabolic syndrome criteria (fasting plasma glucose ¡Ý 6.1 mmol/l, triglycerides ¡Ý 1.7 mmol/l, waist-circumference > 102 cm, HDL-cholesterol < 1.04 mmol/l, blood pressure ¡Ý 130/85 mmHg)
Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)
- Use of any medication, including proton pomp inhibitors and antibiotics in the past three months
- Cholecystectomy
- A history of cardiovascular event (MI or pacemaker implantation)
- (expected) prolonged compromised immunity (due to recent cytotoxic chemotherapy or HIV infection with a CD4 count < 240).
- Unmotivated or not able to adhere to a specific diet.
Opzet
Deelname
Opgevolgd door onderstaande (mogelijk meer actuele) registratie
Geen registraties gevonden.
Andere (mogelijk minder actuele) registraties in dit register
Geen registraties gevonden.
In overige registers
| Register | ID |
|---|---|
| NTR-new | NL5828 |
| NTR-old | NTR5983 |
| Ander register | : METC 2016_117 |